PURPOSE: Whether dosimetric advantages of proton beam therapy (PBT) translate to improved clinical outcomes compared with intensity-modulated radiation therapy (IMRT) remains unclear. This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these modalities for esophageal cancer. METHODS: This phase IIB trial randomly assigned patients to PBT or IMRT (50.4 Gy), stratified for histology, resectability, induction chemotherapy, and stage. The prespecified coprimary end points were TTB and PFS. TTB, a composite score of 11 distinct adverse events (AEs), including common toxicities as well as postoperative complications (POCs) in operated patients, quantified the extent of AE severity experienced over the duration of 1 year following treatment. The trial was conducted using Bayesian group sequential design with three planned interim analyses at 33%, 50%, and 67% of expected accrual (adjusted for follow-up). RESULTS: This trial (commenced April 2012) was approved for closure and analysis upon activation of NRG-GI006 in March 2019, which occurred immediately prior to the planned 67% interim analysis. Altogether, 145 patients were randomly assigned (72 IMRT, 73 PBT), and 107 patients (61 IMRT, 46 PBT) were evaluable. Median follow-up was 44.1 months. Fifty-one patients (30 IMRT, 21 PBT) underwent esophagectomy; 80% of PBT was passive scattering. The posterior mean TTB was 2.3 times higher for IMRT (39.9; 95% highest posterior density interval, 26.2-54.9) than PBT (17.4; 10.5-25.0). The mean POC score was 7.6 times higher for IMRT (19.1; 7.3-32.3) versus PBT (2.5; 0.3-5.2). The posterior probability that mean TTB was lower for PBT compared with IMRT was 0.9989, which exceeded the trial's stopping boundary of 0.9942 at the 67% interim analysis. The 3-year PFS rate (50.8% v 51.2%) and 3-year overall survival rates (44.5% v 44.5%) were similar. CONCLUSION: For locally advanced esophageal cancer, PBT reduced the risk and severity of AEs compared with IMRT while maintaining similar PFS.
RCT Entities:
PURPOSE: Whether dosimetric advantages of proton beam therapy (PBT) translate to improved clinical outcomes compared with intensity-modulated radiation therapy (IMRT) remains unclear. This randomized trial compared total toxicity burden (TTB) and progression-free survival (PFS) between these modalities for esophageal cancer. METHODS: This phase IIB trial randomly assigned patients to PBT or IMRT (50.4 Gy), stratified for histology, resectability, induction chemotherapy, and stage. The prespecified coprimary end points were TTB and PFS. TTB, a composite score of 11 distinct adverse events (AEs), including common toxicities as well as postoperative complications (POCs) in operated patients, quantified the extent of AE severity experienced over the duration of 1 year following treatment. The trial was conducted using Bayesian group sequential design with three planned interim analyses at 33%, 50%, and 67% of expected accrual (adjusted for follow-up). RESULTS: This trial (commenced April 2012) was approved for closure and analysis upon activation of NRG-GI006 in March 2019, which occurred immediately prior to the planned 67% interim analysis. Altogether, 145 patients were randomly assigned (72 IMRT, 73 PBT), and 107 patients (61 IMRT, 46 PBT) were evaluable. Median follow-up was 44.1 months. Fifty-one patients (30 IMRT, 21 PBT) underwent esophagectomy; 80% of PBT was passive scattering. The posterior mean TTB was 2.3 times higher for IMRT (39.9; 95% highest posterior density interval, 26.2-54.9) than PBT (17.4; 10.5-25.0). The mean POC score was 7.6 times higher for IMRT (19.1; 7.3-32.3) versus PBT (2.5; 0.3-5.2). The posterior probability that mean TTB was lower for PBT compared with IMRT was 0.9989, which exceeded the trial's stopping boundary of 0.9942 at the 67% interim analysis. The 3-year PFS rate (50.8% v 51.2%) and 3-year overall survival rates (44.5% v 44.5%) were similar. CONCLUSION: For locally advanced esophageal cancer, PBT reduced the risk and severity of AEs compared with IMRT while maintaining similar PFS.
Authors: Steven H Lin; Ning Zhang; Joy Godby; Jingya Wang; Gary D Marsh; Zhongxing Liao; Ritsuko Komaki; Linus Ho; Wayne L Hofstetter; Stephen G Swisher; Reza J Mehran; Thomas A Buchholz; Linda S Elting; Sharon H Giordano Journal: Cancer Date: 2015-12-30 Impact factor: 6.860
Authors: Michael D Chuong; Christopher L Hallemeier; Salma K Jabbour; Jen Yu; Shahed Badiyan; Kenneth W Merrell; Mark V Mishra; Heng Li; Vivek Verma; Steven H Lin Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-14 Impact factor: 7.038
Authors: Mian Xi; Cai Xu; Zhongxing Liao; Joe Y Chang; Daniel R Gomez; Melenda Jeter; James D Cox; Ritsuko Komaki; Reza Mehran; Mariela A Blum; Wayne L Hofstetter; Dipen M Maru; Manoop S Bhutani; Jeffrey H Lee; Brian Weston; Jaffer A Ajani; Steven H Lin Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-27 Impact factor: 7.038
Authors: Xiaodong Zhang; Kuai-le Zhao; Thomas M Guerrero; Sean E McGuire; Brian Yaremko; Ritsuko Komaki; James D Cox; Zhouguang Hui; Yupeng Li; Wayne D Newhauser; Radhe Mohan; Zhongxing Liao Journal: Int J Radiat Oncol Biol Phys Date: 2008-09-01 Impact factor: 7.038
Authors: Shahed N Badiyan; Lindsay L Puckett; Gregory Vlacich; Walter Schiffer; Lauren N Pedersen; Joshua D Mitchell; Carmen Bergom Journal: Curr Treat Options Oncol Date: 2022-09-10
Authors: Jana M Kobeissi; Charles B Simone; Lara Hilal; Abraham J Wu; Haibo Lin; Christopher H Crane; Carla Hajj Journal: Cancers (Basel) Date: 2022-06-10 Impact factor: 6.575
Authors: Paul D Brown; Caroline Chung; Diane D Liu; Sarah McAvoy; David Grosshans; Karine Al Feghali; Anita Mahajan; Jing Li; Susan L McGovern; Mary-Fran McAleer; Amol J Ghia; Erik P Sulman; Marta Penas-Prado; John F de Groot; Amy B Heimberger; Jihong Wang; Terri S Armstrong; Mark R Gilbert; Nandita Guha-Thakurta; Jeffrey S Wefel Journal: Neuro Oncol Date: 2021-08-02 Impact factor: 12.300
Authors: Andrew J Bishop; J Andrew Livingston; Matt S Ning; Isaac D Valdez; Cody A Wages; Mary Fran McAleer; Arnold C Paulino; David R Grosshans; Kristina D Woodhouse; Randa Tao; Michael E Roth; G Brandon Gunn; Susan L McGovern Journal: Int J Radiat Oncol Biol Phys Date: 2021-03-04 Impact factor: 8.013
Authors: Sabine Visser; Hendrike Neh; Cássia Oraboni Ribeiro; Erik W Korevaar; Arturs Meijers; Björn Poppe; Nanna M Sijtsema; Stefan Both; Johannes A Langendijk; Christina T Muijs; Antje C Knopf Journal: Med Phys Date: 2021-08-05 Impact factor: 4.506